Table 2.
Pharmacokinetic Parameters in Escitalopram-Treated Adolescents
| Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid metabolizer | Ultrarapid metabolizer | |
|---|---|---|---|---|---|
| Cl-m | 13 | 21 | 33 | 45 | 60 |
| t½ (h) | 57.55 | 35.97 | 23.02 | 16.93 | 12.51 |
| AUC24,10 mg q.d. (days•ng/mL) | 44.14 | 27.26 | 17.13 | 12.37 | 8.92 |
| Cmax, 10 mg q.d. ng/mL) | 48.38 | 32.01 | 22.26 | 17.71 | 14.47 |
| AUC24, 20 mg q.d. (days•ng/mL) | 88.29 | 54.52 | 34.26 | 24.74 | 17.85 |
| Cmax, 20 mg q.d. (ng/mL) | 96.78 | 64.03 | 44.51 | 35.43 | 28.93 |
| AUC24, 10 mg b.i.d. (days•ng/mL) | 38.02 | 27.62 | 20.08 | ||
| Cmax,10mg b.i.d. (ng/mL) | 38.53 | 29.28 | 22.59 | ||
| AUC24,15 mg b.i.d. (days•ng/mL) | 41.44 | 30.14 | |||
| Cmax, 15 mg b.i.d. (ng/mL) | 43.92 | 33.89 | |||
| AUC24, 20 mg b.i.d. (days•ng/mL) | 40.18 | ||||
| Cmax,20 mg b.i.d. (ng/mL) | 45.18 | ||||
| PGx-guided dose mg q.d. | 10 | 15 | 20 | 25 | 30 |
| AUC24, PGx-guided dose (days•ng/mL) | 44.15 | 40.89 | 34.26 | 30.92 | 26.77 |
| Cmax, PGx-guided dose (ng/mL) | 48.39 | 48.02 | 44.51 | 44.29 | 43.4 |
Cl-m, clearance; t½, half life; AUC24, area under the curve (24-hour); q.d., quaque die (once daily); b.i.d., bis in die (twice daily); PGx, pharmacogenetic.